The Trial of Pessary After Laser for TTTS (PECEPLASER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01334489|
Recruitment Status : Recruiting
First Posted : April 13, 2011
Last Update Posted : March 31, 2017
|Condition or disease||Intervention/treatment|
|Premature Birth||Device: Arabin Cervical Pessary|
Monochorionic (MC) twin pregnancies present with a high rate of fetal complications, most of them associated with the placental vascular anastomoses. Fetoscopic laser coagulation (FLC) is a surgical technique that allows minimally invasive access into the uterus and has emerged as a useful tool in the management of the most common and severe of these complications, twin to twin transfusion syndrome (TTTS). Even though, preterm birth remains a common cause of adverse outcome because TTTS is associated with a 29% risk of delivering before 28 weeks.
A short cervical length (CL), defined as a CL ≤ 25 mm, detected by transvaginal ultrasound is an independent risk factor for preterm birth in twin pregnancies but no effective treatment has been described to prevent it.
Although is usually accepted that in twin pregnancies cerclage may increase the risk of preterm birth, Salomon and co-workers, found that in cases of TTTS with a CL below the 5th percentile (15 mm) at the time of surgery, performing an emergency cerclage prolonged the pregnancy and allow for better outcome, But still preterm birth after FLC remains a big challenge, so new methods to prevent it must be investigated.
Previous studies in singletons and twins have shown that the use of cervical pessary significantly reduces the frequency of birth before 32 weeks and prolongs pregnancy. The advantage of using cervical pessary is that it is less invasive than cerclage and can be removed easily. That's the reason why pessaries could be considered an alternative, non invasive option to prevent preterm birth in cases of twin to twin transfusion syndrome (TTTS) treated by laser surgery.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||352 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Arabin Cervical Pessary for Prevention of Preterm Birth in Cases of Twin-to-twin Transfusion Syndrome Treated by Fetoscopic Laser Coagulation: The PECEP Laser Trial|
|Actual Study Start Date :||December 2012|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||June 2018|
No Intervention: Usual management
Usual management of monochorionic pregnancy without the pessary placement
Arabin Cervical Pessary
The pessary will be inserted 24 hours after fetal surgery in the exploration room. This procedure does not need anaesthesia and it does not need to be done in a surgery room. During the following explorations the correct placement of the pessary is assessed, and if it does not, it can be easily adjusted.
The pessary will be removed at 37 weeks of gestation, or before if any unexpected event occurs.
Device: Arabin Cervical Pessary
The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).
It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
- Delivery before 32 weeks [ Time Frame: Within the first 15 days after delivery ]Rate of delivery before 32 weeks
- Birth weight [ Time Frame: Within the first 15 days after delivery ]Median weight (g) of the newborns at birth.
- Fetal or neonatal death [ Time Frame: Within the first 15 days after the death ]Rate of intrauterine demise or neonatal death during the first 24 hours.
- Neonatal morbidity [ Time Frame: 30 days after the discharge from the hospital ]Rate of major adverse neonatal outcomes before discharge from the hospital.
- Significant maternal adverse events [ Time Frame: Within 15 days after discharge from the hospital ]Rate of heavy bleeding (bleeding that requires a medical intervention), cervical tear (cervical rupture due to the pessary placement), and/or uterine rupture (rupture of the uterus due to contractions or surgery).
- Physical or psychological intolerance to pessary [ Time Frame: Within 15 days after discharge from hospital ]Discomfort or pain due to the pessary that makes daily life uncomfortable (number of cases).
- Preterm birth before 37 weeks [ Time Frame: Within 15 days after delivery ]Rate of delivery before 36+6 weeks
- Rupture of membranes before 32 weeks [ Time Frame: Within 15 days after delivery ]Rupture of amniotic membranes before 31+6 weeks
- Hospitalisation for threatened preterm labour before 32 weeks [ Time Frame: Within 15 days after delivery ]Requirement of hospitalisation due to preterm contractions that need medical treatment to try to stop them before 31+6 weeks (rate).
- Time to birth [ Time Frame: Within 15 days after delivery ]
- Preterm birth before 34 weeks [ Time Frame: Within 15 days after delivery ]rate of delivery before 33+6 weeks
- Preterm birth before 30 weeks [ Time Frame: Within 15 days after delivery ]rate of delivery before 29+6 weeks
- Preterm birth before 28 weeks [ Time Frame: Within 15 days after delivery ]rate of delivery before 27+6 weeks
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01334489
|Contact: Carlota Rodo, MDemail@example.com|
|Contact: Elena Carreras, PhDfirstname.lastname@example.org|
|UZ Leuven. Campus Gasthuisberg||Not yet recruiting|
|Leuven, Belgium, 3000|
|Contact: Liesbeth Lewi, PhD +32 16 34 28 62 Liesbeth.Lewi@uzleuven.be|
|Contact: Isabel Couk, MD email@example.com|
|University Medical Center Eppendorf||Not yet recruiting|
|Hamburg, Germany, 20246|
|Contact: Kurt Hecher, PhD firstname.lastname@example.org|
|Contact: Bettina Hollowitz, MD +49-40-7410-20321 email@example.com|
|Hospital Universitari Vall d'Hebron||Recruiting|
|Barcelona, Spain, 08035|
|Contact: Carlota Rodo, MD 0034-934893072 firstname.lastname@example.org|
|Contact: Arevalo Silvia, MD 0034-934893072 email@example.com|
|Principal Investigator: Elena Carreras, PhD|
|Principal Investigator: Carlota Rodo, MD|
|Sub-Investigator: Silvia Arevalo, MD|
|Sub-Investigator: Anna Maroto, MD|
|Principal Investigator:||Elena Carreras, PhD||Hospital Vall d'Hebron|